Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vivus Inc VVUSQ

Healthcare Biotechnology
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic... see more

Recent & Breaking News (OTCPK:VVUSQ)

VIVUS Announces Date of 2018 Annual Meeting

GlobeNewswire May 4, 2018

VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE®

GlobeNewswire May 1, 2018

VIVUS Restructures Debt and Gains Access to New Capital

GlobeNewswire May 1, 2018

VIVUS Strengthens Executive Leadership Team

Marketwired April 30, 2018

VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018

MarketWire Canada April 25, 2018

Developments in the Obesity Treatment Market

PR Newswire March 16, 2018

VIVUS Reports Fourth Quarter 2017 Financial Results

MarketWire Canada March 13, 2018

5 Stocks To Watch For December 27, 2017

Benzinga.com  December 27, 2017

VIVUS Announces Change in Leadership

MarketWire Canada December 26, 2017

VIVUS Reports Third Quarter 2017 Financial Results

MarketWire Canada November 7, 2017

VIVUS, Inc. to Host Earnings Call

Accesswire November 7, 2017

VIVUS Completes Tacrolimus Pre-IND Meeting With FDA

Marketwired November 2, 2017

VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017

MarketWire Canada October 31, 2017

Technical Reports on Biotech Equities -- Teligent, VIVUS, Kadmon, and Intrexon

PR Newswire October 24, 2017

VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension

MarketWire Canada September 6, 2017

VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea

Marketwired September 5, 2017

Technical Insights on Biotech Stocks -- Grifols, Halozyme Therapeutics, Illumina, and VIVUS

PR Newswire September 1, 2017

VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation

Marketwired August 30, 2017

Developments in the Erectile Dysfunction Markets

PR Newswire August 28, 2017

VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017

MarketWire Canada August 22, 2017